Browse by ▼

Nektar Therapeutics

  • 1 Large Cap, 2 Small Cap BioPharma Stocks to Consider Buying

    By David Gould - December 10, 2012 | Tickers: AMGN, ENZN, NKTR

    If you are looking to buy stock in biotech, there are several variables you should consider. Growth rates for products and even the potential growth rate for catalysts are critical to any analysis. To spread out risk and still gain exposure to undervalued drugs, I recommend buying stakes in large BioPharma companies, but an even greater stake in their smaller cap buyout peers. Below, I review three stocks with this more »

  • Healthcare Hedge Fund is Selling This Pharma Stock, Should You Too?

    By Meena Krishnamsetty - October 8, 2012 | Tickers: ALKS, HSP, NKTR, PCRX, RIGL

    Between April and June of this year, Orbimed Advisors sold 18% of its shares of Pacira Pharmaceuticals (NASDAQ: PCRX), finishing the second quarter with exactly 2 million shares in its portfolio. According to a more recent 13F filing with the SEC, Orbimed has continued selling shares during the third quarter, and as of September 25th owned just over 1.6 million shares, placing it under the 5% ownership mark more »

  • Four Important Biotech Stocks Targeting Unmet Needs

    By Streetwise Reports - September 1, 2012 | Tickers: ACOR, AMRN, NKTR, NBIX

    By George S. Mack, The Life Sciences Report

     

    Biotech rallies need catalysts to be sustained. Market moving events include drug approvals, such as a couple of obesity products from VIVUS Inc. and Arena Pharmaceuticals Inc., as well as a product to help control serum lipids from Amarin Corp. Plc (NASDAQ: AMRN). But the major diagnostic feature of a market that might be putting it all together is merger and acquisition more »

  • Buy or Hold This Biopharmaceutical

    By Krishna Maheshwari - August 15, 2012 | Tickers: LLY, MNKD, NKTR, NVO, PFE

    Mannkind (NASDAQ: MNKD) is an inhalable drug company developing a fast acting, inhalable insulin (branded Afrezza) that is superior to any other insulin in the market today and a likely blockbuster drug.  They have completed phase III clinical trials and received no drug efficacy related pushback from the FDA, but have received two CRLs recently.  They are currently conducting two clinical trials to prove that the inhaler they intend to more »